Evidence map›Paper›PMID 34709680›Full record

ArticleTransplant international : official journal of the European Society for Organ Transplantation2021

COVID-19 in lung transplant recipients: an overview of the Swedish national experience.

Jesper M Magnusson, Hillevi Larsson, Ahmed Alsaleh, Jan Ekelund, Kristjan Karason, Andreas Schult, Vanda Friman, Marie Felldin, John Mackay Søfteland, Göran Dellgren and 1 more

Abstract read
In one paragraph

Article in Transplant international : official journal of the European Society for Organ Transplantation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Impact of COVID-19 on lung transplant recipients: Only time will tell.Transplant infectious disease : an official journal of the Transplantation Society · 2022
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jesper M MagnussonDepartment of Pulmonology, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0002-5630-0155
Hillevi LarssonDepartment of Pulmonology, Skåne University Hospital, Lund, Sweden.
Ahmed AlsalehDepartment of Radiology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Jan EkelundCentre of Registers Västra Götaland, Gothenburg, Sweden.
Kristjan KarasonThe Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden.
Andreas SchultThe Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden.ORCID 0000-0002-2082-8724
Vanda FrimanDepartment of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0002-0361-4222
Marie FelldinThe Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden.ORCID 0000-0003-1618-0272
John Mackay SøftelandThe Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden.ORCID 0000-0001-7993-5906
Göran DellgrenThe Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden.ORCID 0000-0003-4961-9704
Mihai OlteanThe Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden.ORCID 0000-0003-3783-5207

Funding

Mr Paul Frankenius Private contribution to fund the ethical application
6 · The paper itself

Abstract

Although it is known that solid organ transplant recipients fare worse after COVID-19 infection, data on the impact of COVID-19 on clinical outcomes and allograft function in lung transplant (LTx) recipients are limited and based mainly on reports with short follow-up. In this nationwide study, all LTx recipients with COVID-19 diagnosed from 1 February 2020 to 30 April 2021 were included. The patients were followed until 1 August 2021 or death. We analysed demographics, clinical features, therapeutic management and outcomes, including lung function. Forty-seven patients were identified: median age was 59 (10-78) years, 53.1% were male, and median follow-up was 194 (23-509) days. COVID-19 was asymptomatic or mild at presentation in 48.9%. Nine patients (19.1%) were vaccinated pre-COVID infection. Two patients (4.3%) died within 28 days of testing positive, and the overall survival rate was 85.1%. The patients with asymptomatic or mild symptoms had a higher median % expected forced expiratory volume during the first second than the patients with worse symptoms (P = 0.004). LTx recipients develop the entire spectrum of COVID-19, and in addition to previously acknowledged risk factors, lower pre-COVID lung function was associated with more severe disease presentation.

Indexed as

COVID-19Lung TransplantationHumansLungMaleMiddle AgedRetrospective StudiesSARS-CoV-2SwedenTransplant RecipientsCOVID-19lung functionlung transplantationmulticentre studyseveritysurvival

Identifiers

PMID34709680
PMCPMC8646614

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.